Merck Strengthens Executive Board

Darmstadt, Germany (ots/PRNewswire) -

- Stefan Oschmann appointed Deputy CEO and Vice Chairman of the Executive
Board
- Belen Garijo appointed new member of the Executive Board
- Changes effective from January 1, 2015

Merck today announced that the Board of Partners has promoted
Stefan Oschmann (57) to the position of Deputy CEO and Vice Chairman
of the Executive Board. Concurrently, Belen Garijo (54) was appointed
to the Executive Board to take over leadership for the Pharma
business. The management changes will become effective as of January
1, 2015.

(Photo: http://photos.prnewswire.com/prnh/20140924/706485-a )

(Photo: http://photos.prnewswire.com/prnh/20140924/706485-b )

Oschmann, currently CEO Pharma, will represent Karl-Ludwig Kley,
Chairman of the Executive Board. Both will share strategic management
functions and will represent the company with politicians and
international organizations.

As a member of the Executive Board, Garijo, currently CEO of
Merck's biopharmaceutical division Merck Serono, will take on
responsibility for the whole Pharma business. Besides Merck Serono,
this includes Consumer Health, Allergy and Biosimilars.

"With today's management decisions we strengthen Merck's
leadership team and prepare the ground for continuity to reach our
ambitious growth targets until the year 2018 and beyond," said
Johannes Baillou, Chairman of the Board of Partners of E. Merck KG.
"Stefan Oschmann who has successfully reorganized our pharma
businesses over the past years will familiarize himself with
Group-wide functions and will increasingly assume external
responsibilities for the company. Belen Garijo has many years of
experience in the pharma industry, has proven that she can further
develop our business organization and in her future role will provide
a significant contribution to ensure the sustainable success of our
pharma businesses."

Note to editors

You find pictures and CVs here
[http://cc-special.merck.de/Internet/Media/zip/Announcement_EN.zip ].

All Merck Press Releases are distributed by e-mail at the same
time they become available on the Merck Website. Please go to
http://www.merckgroup.com/subscribe to register online, change your
selection or discontinue this service.

Merck is a leading company for innovative and top-quality
high-tech products in the pharmaceutical and chemical sectors. With
its four divisions Merck Serono, Consumer Health, Performance
Materials and Merck Millipore, Merck generated total revenues of EUR
11.1 billion in 2013. Around 39,000 Merck employees work in 66
countries to improve the quality of life for patients, to further the
success of our customers and to help meet global challenges. Merck is
the world's oldest pharmaceutical and chemical company - since 1668,
the company has stood for innovation, business success and
responsible entrepreneurship. Holding an approximately 70% interest,
the founding family remains the majority owner of the company to this
day. Merck, Darmstadt, Germany is holding the global rights to the
Merck name and brand. The only exceptions are Canada and the United
States, where the company is known as EMD.

Photo:
http://photos.prnewswire.com/prnh/20140924/706485-a

http://photos.prnewswire.com/prnh/20140924/706485-b

ots Originaltext: Merck KGaA
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Contact: Merck KGaA, Frankfurter Straße 250, 64293 Darmstadt,
Hotline +49-6151-72-5000, www.merckgroup.com ; Leitung Media
Relations
-62445, Pressesprecher: -9591 / -7144 / -6328, Fax +49-6151-72-3138,
media.relations@merckgroup.com